Scott Fleming

Biography

Scott is a founding member of the digital drug delivery movement. With 25 years’ sector experience covering strategy, drug device development, and sales & marketing.After gaining an interest in drug delivery performing Business Development at the PA Consulting Group, Scott co-founded MicroDose Therapeutx in 1997, developing the first totally digital dry powder inhaler. During his tenure as Sr. Vice President and Board Member, he led MicroDose’s strategy and executed numerous licensing and development collaborations with Bristol-Myers Squibb, Novartis AG, Merck & Co. and Gilead Sciences Inc., among others, for respiratory programs using the digital inhaler and associated in-house molecules.Scott engineered the sale of MicroDose to Teva Pharmaceuticals in 2013, and took on a key role as the Global Brand Lead for eConnectivity of Teva’s respiratory franchise based in Amsterdam, NL responsible for the commercial and branding strategy for eConnectivity of Teva’s inhaler products.Scott is based in Amsterdam, the Netherlands, where Adherium’s European operations is located and will continue to develop Adherium’s partnerships within the key European market and beyond.Scott graduated cum laude from Middlebury College with Bachelor of Science and Bachelor of Arts degrees in Geology and Music respectively and spent 11 years in the petroleum industry with Schlumberger Ltd before moving to the healthcare industry.

Research Interest

 Drug Delivery,Drug Device Development,Digital Inhaler and associated In-House Molecules